Compare LyondellBasell Industries NV (LYB) vs Sanofi SA (SNY) Price & Performance

LYB trades at $60.03, up 2.63% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $4.30 beating expectations of $3.44, but faces fundamental challenges with negative net income margin of -1.13% and declining revenue from $50.5B in 2022 to $30.2B in 2025. Analyst consensus remains divided with 45% buy and 45% hold ratings, targeting $69.38 average price.

LYB shows operational resilience with improving cash flow projections for 2026, but faces significant headwinds from declining profitability and competitive pressures. The dividend yield remains attractive but sustainability concerns persist given the negative earnings trend. Near-term upside exists if operational improvements continue, though investors should monitor debt levels and chemical sector cyclicality.

Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.

The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.